ATE331800T1 - Regulation der transcription in säugetierzellen und viraler replikation durch eine tetracyclinrepressor - Google Patents

Regulation der transcription in säugetierzellen und viraler replikation durch eine tetracyclinrepressor

Info

Publication number
ATE331800T1
ATE331800T1 AT98924964T AT98924964T ATE331800T1 AT E331800 T1 ATE331800 T1 AT E331800T1 AT 98924964 T AT98924964 T AT 98924964T AT 98924964 T AT98924964 T AT 98924964T AT E331800 T1 ATE331800 T1 AT E331800T1
Authority
AT
Austria
Prior art keywords
repressor
transcription
regulation
viral replication
tetracycline repressor
Prior art date
Application number
AT98924964T
Other languages
English (en)
Inventor
Feng Yao
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Application granted granted Critical
Publication of ATE331800T1 publication Critical patent/ATE331800T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF] (urogastrone)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT98924964T 1997-06-26 1998-05-29 Regulation der transcription in säugetierzellen und viraler replikation durch eine tetracyclinrepressor ATE331800T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/883,327 US5972650A (en) 1997-06-26 1997-06-26 Tetracycline repressor regulated mammalian cell transcription and viral replication switch

Publications (1)

Publication Number Publication Date
ATE331800T1 true ATE331800T1 (de) 2006-07-15

Family

ID=25382404

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98924964T ATE331800T1 (de) 1997-06-26 1998-05-29 Regulation der transcription in säugetierzellen und viraler replikation durch eine tetracyclinrepressor

Country Status (7)

Country Link
US (3) US5972650A (de)
EP (1) EP0990041B1 (de)
JP (3) JP3577323B2 (de)
AT (1) ATE331800T1 (de)
CA (1) CA2293612C (de)
DE (1) DE69835085T2 (de)
WO (1) WO1999000510A1 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972650A (en) * 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
AU4924199A (en) * 1998-07-30 2000-02-21 Advec, Inc. Repressor proteins producing cell lines for the propagation of vectors
EP1135461A4 (de) * 1998-12-02 2003-03-26 Univ Boston Gen-netzwerke zur kontrolle der genexpression
EP1203084A1 (de) * 1999-07-30 2002-05-08 University College London Stickstoffmonoxid-synthase-quelle in mikrokapseln
EP1083230A1 (de) * 1999-09-10 2001-03-14 Academisch Medisch Centrum Amsterdam Virale Replikons und von induzierenden Wirkstoffen abhängige Viren
GB0015090D0 (en) * 2000-06-20 2000-08-09 Implyx Ltd Gene-activating conjugates
CA2420944A1 (en) 2000-08-30 2002-03-07 Chemocentryx, Inc. Inhibition of cmv infection and dissemination
AU2001293798B2 (en) * 2000-09-09 2006-12-21 Basf Plant Science Gmbh Modified tet-inducible system for regulation of gene expression in plants
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
WO2002062296A2 (en) * 2001-02-02 2002-08-15 Chemocentryx, Inc. Methods and compositions useful for stimulating an immune response
GB0106786D0 (en) * 2001-03-19 2001-05-09 Gendaq Ltd Gene regulation
EP1385946B1 (de) * 2001-05-01 2009-12-23 National Research Council Of Canada Induzierbares expressionssystem in eukaryotischen zellen
ATE527347T1 (de) * 2001-08-02 2011-10-15 Inst Clayton De La Rech Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen
JP2005503797A (ja) * 2001-09-13 2005-02-10 ジェンベク、インコーポレイティッド アデノウイルスベクター及び関連する系、並びに製造及び使用の方法
IL161229A0 (en) * 2001-10-02 2004-09-27 Inst Clayton De La Rech Methods and compositions relating to restricted expression lentiviral vectors and their applications.
JP4817657B2 (ja) * 2002-05-29 2011-11-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 誘導性の真核生物発現システム
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
US20040126789A1 (en) * 2002-09-05 2004-07-01 Invitrogen Corporation Compositions and methods for synthesizing nucleic acids
US20050071893A1 (en) * 2002-10-17 2005-03-31 Jost Seibler SiRNA mediated gene silencing in transgenic animals
WO2004048583A2 (en) * 2002-11-22 2004-06-10 Institut Clayton De La Recherche Compositions and systems for the regulation of genes
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
EP2418281B1 (de) 2003-10-24 2016-06-01 Gencia Corporation Verfahren und Zusammensetzungen zur Abgabe von Polynukleotiden
US20050164210A1 (en) * 2004-01-23 2005-07-28 Vivek Mittal Regulated polymerase III expression systems and related methods
US9273326B2 (en) * 2004-04-30 2016-03-01 The Brigham And Women's Hospital, Inc. Tetracycline-regulated gene expression in HSV-1 vectors
CA2587712C (en) * 2004-11-18 2013-02-12 National University Of Corporation Hiroshima University Method and kit for expressing protein under regulation of the expression from repeated sequence formed by gene amplification and transformant
WO2007073513A2 (en) 2005-11-10 2007-06-28 Genvec, Inc. Method for propagating adenoviral vectors encoding inhibitory gene products
US20080008686A1 (en) * 2006-07-10 2008-01-10 The Brigham And Women's Hospital, Inc. Tetracycline repressor regulated oncolytic viruses
CA2660321A1 (en) * 2006-08-10 2008-02-21 The Board Of Trustees Of The Leland Stanford Junior University Differential labeling of cells
ATE495239T1 (de) * 2007-03-09 2011-01-15 Vectorlogics Inc Zellen für adenovirusvektor- und proteinherstellung
US8645115B2 (en) 2008-12-22 2014-02-04 Trustees Of Boston University Modular nucleic acid-based circuits for counters, binary operations, memory and logic
US8796440B2 (en) 2009-08-31 2014-08-05 The Brigham And Women's Hospital, Inc. Promote system for regulatable gene expression in mammalian cells
WO2011079073A2 (en) 2009-12-21 2011-06-30 The Brigham And Women's Hospital, Inc. Herpes simplex virus vaccines
CA2805915C (en) 2010-07-22 2017-01-24 President And Fellows Of Harvard College Multiple input biologic classifier circuits for cells
ES2931180T3 (es) 2011-05-19 2022-12-27 Fund Publica Andaluza Progreso Y Salud Sistema de tipo Tet-on lentivírico de promotor dual muy inducible
WO2013155439A1 (en) 2012-04-13 2013-10-17 Massachusetts Institute Of Technology Analog and mixed-signal computation and circuits in living cells
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
CA2905049A1 (en) 2013-03-13 2014-10-02 Trustees Of Boston University Tunable control of protein degradation in synthetic and endogenous bacterial systems
CN105026423A (zh) 2013-03-14 2015-11-04 瑞泽恩制药公司 爱帕琳融合蛋白和其用途
SG10201800772TA (en) 2013-10-11 2018-03-28 Regeneron Pharma Metabolically optimized cell culture
AR102333A1 (es) 2014-08-19 2017-02-22 Regeneron Pharma Selectividad eficiente de proteínas recombinadas
RS58080B1 (sr) 2014-11-04 2019-02-28 Janssen Vaccines & Prevention Bv Terapeutske vakcine protiv hpv16
AU2016309743B2 (en) 2015-08-20 2019-02-07 Janssen Vaccines & Prevention B.V. Therapeutic HPV18 vaccines
US11459573B2 (en) 2015-09-30 2022-10-04 Trustees Of Boston University Deadman and passcode microbial kill switches
JP6937309B2 (ja) * 2016-01-27 2021-09-22 ジャスト−エヴォテック バイオロジックス、インコーポレイテッド ハイブリッドプロモーターおよびその使用
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
WO2017192418A1 (en) 2016-05-02 2017-11-09 Janssen Vaccine & Prevention B.V. Therapeutic hpv vaccine combinations
US20200317738A1 (en) 2016-05-26 2020-10-08 University College Cork - National University Of Ireland, Cork Methods for increasing proliferation of mammalian cells
WO2017203051A1 (en) 2016-05-26 2017-11-30 University College Cork - National University Of Ireland, Cork An engineered gram positive bacterium
BR112019015671A2 (pt) 2017-02-09 2020-04-14 Janssen Vaccines & Prevention Bv promotor potente e curto para expressão de genes heterológicos
CA3073615A1 (en) 2017-08-25 2019-02-28 University College Cork - National University Of Ireland Cork Bifidobacterium longum for treating obesity and weight management
US20200345051A1 (en) 2017-11-24 2020-11-05 University College Cork, National University Of Ireland, Cork A composition comprising a cohort of bacteria
US11390650B2 (en) 2018-02-05 2022-07-19 The Brigham And Women's Hospital, Inc. Recombinant Herpes Simplex Virus-2 expressing glycoprotein B and D antigens
WO2020006409A1 (en) 2018-06-28 2020-01-02 Trustees Of Boston University Systems and methods for control of gene expression
EP3604507A1 (de) 2018-07-30 2020-02-05 University College Cork-National University of Ireland, Cork Omega-transaminase-enzym
EP4017518A1 (de) 2019-08-20 2022-06-29 Nuritas Limited Peptide zur behandlung von muskelatrophie
EP3783012A1 (de) 2019-08-20 2021-02-24 Nuritas Limited Antimikrobielles peptid
CN114980913A (zh) 2019-10-22 2022-08-30 努里塔斯有限公司 非酒精性脂肪性肝病的治疗
EP4135757A1 (de) 2020-04-13 2023-02-22 Janssen Biotech, Inc. Psma- und steap1-impfstoffe und ihre verwendungen
EP4070670A1 (de) 2021-04-08 2022-10-12 University College Cork-National University of Ireland Cork Lacticaseibacillus paracasei em025-11 und verwendungen davon
CA3214581A1 (en) 2021-04-14 2022-10-20 Tom Moore Treatment of cerebrovascular events and neurological disorders
WO2022219168A1 (en) 2021-04-14 2022-10-20 University College Cork - National University Of Ireland, Cork Psg1 for use in the treatment of osteoarthritis
WO2024078729A1 (en) 2022-10-14 2024-04-18 University College Cork - National University Of Ireland, Cork Placenta expressed proteins for use in the treatment of tendon injury

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0823486A3 (de) * 1991-06-27 2004-02-11 Genelabs Technologies, Inc. Verfahren zur Hemmung der Bindung von DNA-Bindungsproteinen mit Duplex-DNA
WO1993001301A1 (en) * 1991-07-05 1993-01-21 The Penn State Research Foundation Mutant antiviral regulatory proteins
US5917122A (en) * 1992-08-26 1999-06-29 Byrne; Guerard Tetracycline repressor-mediated binary regulation system for control of gene expression in transgenic mice
US5589362A (en) * 1993-06-14 1996-12-31 Basf Aktiengesellschaft Tetracycline regulated transcriptional modulators with altered DNA binding specificities
US5464758A (en) * 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5965440A (en) * 1995-12-07 1999-10-12 The General Hospital Corporation Controlled gene product delivery from a regulatable retroviral vector
US5972650A (en) * 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch

Also Published As

Publication number Publication date
JP3769573B2 (ja) 2006-04-26
EP0990041B1 (de) 2006-06-28
WO1999000510A1 (en) 1999-01-07
EP0990041A1 (de) 2000-04-05
JP3577323B2 (ja) 2004-10-13
US20020028484A1 (en) 2002-03-07
DE69835085D1 (de) 2006-08-10
DE69835085T2 (de) 2007-01-18
US5972650A (en) 1999-10-26
US6444871B1 (en) 2002-09-03
JP3638279B2 (ja) 2005-04-13
CA2293612A1 (en) 1999-01-07
JP2005053932A (ja) 2005-03-03
US6251640B1 (en) 2001-06-26
JP2004222733A (ja) 2004-08-12
JP2000515769A (ja) 2000-11-28
CA2293612C (en) 2007-05-08

Similar Documents

Publication Publication Date Title
ATE331800T1 (de) Regulation der transcription in säugetierzellen und viraler replikation durch eine tetracyclinrepressor
Facchiano et al. Promotion of regeneration of corticospinal tract axons in rats with recombinant vascular endothelial growth factor alone and combined with adenovirus coding for this factor
EE04753B1 (et) Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarüootne rakk, meetod rekombinantse hTyr-proteiini valmistamiseks ning vaktsiin
ATE172496T1 (de) Wirt-vektor system zur anwendung in gentherapie
FI951404A0 (fi) Adenovirusvektoreita vieraiden geenien siirtämiseksi keskushermostojärjestelmän, erityisesti aivojen, soluihin
ATE317895T1 (de) Vektoren zur gewebsspezifischen replikation
DE69834936D1 (de) Vektor zur gewebespezifischen replikation und expression
ATE323169T1 (de) Plasmid zur verabreichung von nukleine säuren und verwendungsverfahren
ATE451835T1 (de) Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae
ATE468859T1 (de) Immunogene zusammensetzung und verfahren
ATE337406T1 (de) Replikationsunfähige herpesviren zur verwendung in gentherapie
Razin et al. Nuclear matrix attachment regions and topoisomerase II binding and reaction sites in the vicinity of a chicken DNA replication origin
HUP0002913A2 (hu) Eljárások és készítmények szekretált fehérjéket, például béta-interferont kódoló géneket alkalmazó terápiára
DE602005021159D1 (de) Bakteriophagen- und prophagen-proteine in der krebsgentherapie
Norton et al. Expression of secreted platelet-derived growth factor-B by recombinant nonreplicating and noncytopathic vaccinia virus
DK1032429T3 (da) Fremgangsmåde til DNA-afgivelse in vivo ved anvendelse af et nålefrit apparatur
Kumar et al. Methods, potentials, and limitations of gene delivery to regenerate central nervous system cells
Latchman Progress in Gene Therapy: Basic and Clinical Frontiers, pp. 139-159 R. Bertolotti et al.(Eds)© VSP 2000
WO2003047634A3 (en) Nucleic acids and methods for treating ebv-positive cancers

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties